{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:24:27Z","timestamp":1782321867945,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,2,23]],"date-time":"2007-02-23T00:00:00Z","timestamp":1172188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>The effect of dexamethasone on hepatic and renal P\u2010glycoprotein (P\u2010gp) expression, localization and activity was investigated in rats after 4 days oral administration of two dose regimens (1 or 25\u00a0mg\/kg per day). Simultaneous increases in liver weight were evaluated by quantitative histological examination.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the liver, dexamethasone pretreatment produced hepatomegaly as a consequence of extensive periportal fat accumulation, which was quantified by densitometry of oil red O\u2010stained liver sections. Quantitative immunohistochemical analysis revealed preferential periportal zonation of P\u2010gp in control animals. Dexamethasone pretreatment resulted in spatially disproportional induction of P\u2010gp protein expression within the liver acinus characterized by preferential increase in pericentral areas, with consequent uniform panlobular distribution. Western blot analysis confirmed these results, showing increases in P\u2010gp protein. Quantitative reverse transcription\u2013polymerase chain reaction analysis revealed no statistically significant change in liver <jats:italic>mdr1b<\/jats:italic> mRNA expression after either dexamethasone treatment regimen. The expression of <jats:italic>mdr1a<\/jats:italic> mRNA was significantly decreased by 85\u201387%.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the kidney, dexamethasone reduced <jats:italic>mdr1a<\/jats:italic> mRNA expression by 69\u201389%, whereas <jats:italic>mdr1b<\/jats:italic> mRNA expression was increased in a dose\u2010dependent manner. However, despite tendencies, no significant increases in P\u2010gp expression were observed at the protein level.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The <jats:italic>in vivo<\/jats:italic> function of P\u2010gp was evaluated by measuring renal and biliary secretion of rhodamine\u2010123 (Rho123) under a steady state plasma concentration. The biliary, renal and tubular secretory clearance of Rho123 was significantly increased only after high\u2010dose dexamethasone.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In conclusion, the present study suggests that drug interactions observed during corticosteroid therapy may be mediated, at least in part, through increased biliary, and also renal, excretion of P\u2010gp substrates. Expression of P\u2010gp in the liver showed primary periportal zonation with differential changes during induction. Accompanying hepatomegaly may be explained by severe microvesicular steatosis selectively localized to the periportal areas.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1111\/j.1440-1681.2007.04558.x","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T16:51:12Z","timestamp":1282236672000},"page":"296-303","source":"Crossref","is-referenced-by-count":23,"title":["MORPHOLOGICAL AND FUNCTIONAL CHANGES IN P\u2010GLYCOPROTEIN DURING DEXAMETHASONE\u2010INDUCED HEPATOMEGALY"],"prefix":"10.1111","volume":"34","author":[{"given":"Stanislav","family":"Micuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leos","family":"Fuksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Mundlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Osterreicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Mokry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolana","family":"Cermanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brcakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Staud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Pokorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirina","family":"Martinkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,2,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.7.838"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00169-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199804000-00002"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.25.1604"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00171-0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-120028427"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200211270-00014"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg381"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00147-003-0615-1"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)01663-9"},{"key":"e_1_2_6_12_2","first-page":"145","article-title":"Pharmacokinetic interaction of cytochrome P450 3A\u2010related compounds with rhodamine 123, a P\u2010glycoprotein substrate, in rats pretreated with dexamethasone","volume":"29","author":"Yumoto R","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20102"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/js9901763"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto960322.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1042\/bst022132s","article-title":"Origins of hepatomegaly produced by dexamethasone (DEX), pregnenolone 16 alpha\u2010carbonitrile (PCN) and phenobarbitone (PB) in female Sprague\u2010Dawley rats","volume":"22","author":"Thatcher NJ","year":"1994","journal-title":"Biochem. Soc. Trans."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(98)00086-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05644.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01108.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-198601000-00008"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1998.tb03328.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2004.04.014"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00911-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.05.014"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.130"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/17.3.451"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0014-2956.2001.02540.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011086716568"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3500443"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180528"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.7.1060"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3290017"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00699-3"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3462-3467.2001"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0694-z"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00957-0"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1997.272.5.G1141"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/18.8.1491"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2007.04558.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2007.04558.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:31:45Z","timestamp":1696944705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2007.04558.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,23]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1440-1681.2007.04558.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04558.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,23]]}}}